Full Press Release Details
Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed
BEACH, CA - February 18, 2026 - NorthStrive Biosciences, Inc. ("NorthStrive" or the "Company"),
a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: PMGC), today announced the filing of ten (10) new U.S. patent applications expanding
its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed
to encourage animals to grow new muscle and increase muscle weight return per animal.
ten (10) patent applications include five (5) new patent applications covering EL-22 and five (5) new, corresponding applications covering
EL-32 across multiple farmed animal categories, including livestock, aquaculture, and poultry.
Growth and Increased Yield in Livestock
of the patent applications cover the use of EL-22 and EL-32 as non-feed additive supplements designed to encourage animals to grow new
muscle tissue and increase muscle weight return per animal.
Emissions Reduction and Animal Health
applications cover the use of EL-22 and EL-32 to reduce gaseous emissions in livestock, potentially decreasing environmental impact and
mitigating ruminal tympany risk.
Muscle Growth and Efficiency
have also been filed covering the use of EL-22 and EL-32 in aquaculture to encourage muscle growth in aquatic species, potentially reducing
time to commercially viable size and lowering energy expenditures.
aquaculture filings address emissions reduction to mitigate eutrophic conditions.
final set of applications covers the use of EL-22 and EL-32 in poultry to encourage muscle growth and improve muscle yield per bird within
standard growth timelines.
Northstrive Biosciences Inc.
Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge
aesthetic medicines. Northstrive's lead asset, EL-22, leverages an engineered probiotic approach to address obesity's pressing
issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and
development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value.
For more information, please visit https://www.pmgcholdings.com.
contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects,"
"plans," "potential," "would" and "future" or similar expressions such as "look
forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press
release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy,
activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future,
they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside
of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it
cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ
materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks
are described more fully in PMGC's filings with the United States Securities and Exchange Commission ("SEC"), including
the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed
with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders
are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained
in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes
no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.